All nine patients treated with a personalized cancer vaccine following removal of their tumors remained cancer-free at a median data cut-off of 34.7 months.

Groundbreaking personalized kidney cancer vaccines show promise in early clinical trials, triggering strong immune responses ...

The respiratory syncytial virus (RSV) vaccine produced strong immune responses in older adults during its first two seasons of use, according to a new study.

Compugen's innovative approach targets under-explored immune pathways like PVRIG and IL-18 binding protein. Read why I'm ...

A personalized neoantigen cancer vaccine generated strong immune responses in renal cell carcinoma patients, leading to ...

The U.S. Food and Drug Administration has approved Penmenvy (Meningococcal Groups A, B, C, W, and Y Vaccine) for active ...

When blood cancer cells break through the bone and multiply, tumor cells become dangerously diverse and the immune response ...

The respiratory syncytial virus (RSV) vaccine triggered strong immune responses among people aged 60 years and older during ...

Researchers have found that a small vaccine, currently in its early trial phase, can enhance immune system response to fight advanced kidney cancer. A team of researchers, led by Dr David Braun ...

Explore how T cell engagers could transform cancer and autoimmune treatments through promising trials and key collaborations.

Achieved statistical significance on primary endpoint at Week 12 on mean change from baseline DAS-28 CRP across all rosnilimab doses vs.